Clinical trial
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in…
NCT00081224 · Alliance for Clinical Trials in Oncology, Other · Terminated
Key facts
| NCT number | NCT00081224 |
|---|---|
| Title | Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum |
| Official title | A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | capecitabine, celecoxib, radiation therapy, surgery |
| Enrollment | 3 |
| Start date | Dec 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Nov 1, 2010 |
| First posted | Apr 8, 2004 |
| Last update posted | Dec 15, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: